Concluding Comments/Authors’ Preferences for the Guidelines

  • Xinghuai SunEmail author
  • Yi DaiEmail author


Glaucoma is a group of diseases that require long-term and even life-long treatment. Each ophthalmologist should master the art of glaucoma medical therapy based on scientific understanding of the etiology of glaucoma and the pharmacological mechanisms of anti-glaucoma medications.


Visual function Individualized treatment Quality of life Target pressure 



This book was supported by the top priority of Clinical Medicine Center of Shanghai (2017ZZ01020).


  1. 1.
    Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol. 2002;120:1268–79.CrossRefGoogle Scholar
  2. 2.
    The AGIS Investigators. The advanced glaucoma intervention study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–40.CrossRefGoogle Scholar
  3. 3.
    American Academy of Ophthalmology. Preferred practice pattern. 3rd ed. 2015.Google Scholar
  4. 4.
    European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. 2014.Google Scholar
  5. 5.
    Asia-Pacific Glaucoma Society. Asia Pacific glaucoma guidelines. 3rd ed. 2016.Google Scholar
  6. 6.
    Chinese Glaucoma Society. Expert consensus on the diagnosis and treatment for primary glaucoma. Chin J Ophthalmol. 2014;50(5):382–3.Google Scholar
  7. 7.
    Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–42.CrossRefGoogle Scholar
  8. 8.
    Hedman K, Larsson L-I. The effect of Latanoprost compared with Timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(Suppl 1):S77–89.CrossRefGoogle Scholar
  9. 9.
    Sun X, Lin M, Duan X, Zhang C, Ming J. Patient satisfaction with fixed-combination bimatoprost/timolol ophthalmic solution: a survey study in patients with glaucoma in China. Patient Prefer Adherence. 2017;28(11):845–52.CrossRefGoogle Scholar
  10. 10.
    Sun X, Dai Y, Chen Y, Yu D-Y, Cringle SJ, Chen J, Kong X, Wang X, Jiang C. Primary angle closure glaucoma: What we know and what we don’t know. Prog Retin Eye Res. 2017;57:26–45.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Ophthalmology and Visual ScienceEye and ENT Hospital, Shanghai Medical College, Fudan UniversityShanghaiChina
  2. 2.NHC Key Laboratory of MyopiaFudan UniversityShanghaiChina
  3. 3.Key Laboratory of MyopiaChinese Academy of Medical SciencesShanghaiChina
  4. 4.Shanghai Key Laboratory of Visual Impairment and RestorationFudan UniversityShanghaiChina
  5. 5.State Key Laboratory of Medical NeurobiologyInstitutes of Brain Science and Collaborative Innovation Center for Brain Science, Fudan UniversityShanghaiChina
  6. 6.NHC Key Laboratory of Myopia (Fudan University), Key Laboratory of Myopia, Chinese Academy of Medical SciencesShanghaiChina
  7. 7.Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University)ShanghaiChina

Personalised recommendations